We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.08 | -0.06% | 130.04 | 540 | 12:35:37 |
From Apr 2021 to Apr 2024
By Matt Grossman
Merck & Co. Inc. said Tuesday that its islatravir investigational drug for preventing HIV-1 infection was well-tolerated by patients through 24 weeks of a Phase 2a study.
Most adverse events were mild and there were no serious drug-related adverse events among patients who got the drug, Merck said. Blood levels remained above the pre-specified efficacy threshold eight weeks after the last study dose at two separate dose levels, according to the company.
Merck is studying the drug's use as pre-exposure prophylaxis for adults with low risk of contracting HIV-1 in a study that included 242 people. Dr. Joan Butterson, the vice president for global clinical development in infectious diseases for Merck Research Laboratories, said the results provided "encouraging support."
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 20, 2021 06:37 ET (10:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
